Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
320 West 37 Th Street, New York, New York
State of incorporation
Delaware
Fiscal year end
March 31
Former names
Health Sciences Acquisitions Corp (to 12/20/2019)
Latest financial report
Q1 2024 - May 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % -7.48%
Debt-to-equity 9.32 % +7.62%
Return On Equity -64.5 % -43.4%
Return On Assets -59.3 % -41.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 146M shares +11.8%
Common Stock, Shares, Outstanding 146M shares +11.7%
Entity Public Float 2.18B USD +811%
Common Stock, Value, Issued 14K USD +7.69%
Weighted Average Number of Shares Outstanding, Basic 138M shares +12.2%
Weighted Average Number of Shares Outstanding, Diluted 138M shares +12.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 128M USD +60.3%
General and Administrative Expense 57.3M USD +19.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -259M USD -22.7%
Income Tax Expense (Benefit) 567K USD +6200%
Net Income (Loss) Attributable to Parent -259M USD -22.9%
Earnings Per Share, Basic -1.88 USD/shares -9.94%
Earnings Per Share, Diluted -1.88 USD/shares -9.94%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 635M USD +68.7%
Accounts Receivable, after Allowance for Credit Loss, Current 5.34M USD +662%
Assets, Current 666M USD +64.7%
Property, Plant and Equipment, Net 462K USD +38.7%
Operating Lease, Right-of-Use Asset 133K USD -88.7%
Assets 666M USD +64.2%
Accounts Payable, Current 7.16M USD +429%
Accrued Liabilities, Current 41.3M USD +2.18%
Liabilities, Current 48.6M USD +12.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 48.6M USD +12.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.91M USD +124%
Retained Earnings (Accumulated Deficit) -826M USD -45.8%
Stockholders' Equity Attributable to Parent 618M USD +70.4%
Liabilities and Equity 666M USD +64.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -214M USD -13.8%
Net Cash Provided by (Used in) Financing Activities 472M USD +566%
Net Cash Provided by (Used in) Investing Activities -360K USD -82.7%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 146M shares +11.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 259M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 635M USD +68.7%
Deferred Tax Assets, Valuation Allowance 141M USD +53.8%
Deferred Tax Assets, Gross 142M USD +53.3%
Operating Lease, Liability 138K USD -88.7%
Depreciation 231K USD +19.7%
Payments to Acquire Property, Plant, and Equipment 360K USD +82.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -258M USD -22.7%
Lessee, Operating Lease, Liability, to be Paid 141K USD -88.7%
Operating Lease, Liability, Current 138K USD -88.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 47K USD -96.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 141K USD -88.2%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -88%
Lessee, Operating Lease, Liability, to be Paid, Year Three 47K USD -95.8%
Deferred Tax Assets, Operating Loss Carryforwards 98.2M USD +52.5%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) 567K USD +6200%
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 1.2M USD 0%
Additional Paid in Capital 1.44B USD +55.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 347K USD -30.9%
Share-based Payment Arrangement, Expense 41M USD +28.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%